Biohaven announced that it has received a Complete Response Letter (CRL) from the U.S. Food and Drug Administration (FDA) for the New Drug Application (NDA) seeking approval of VYGLXIA (troriluzole) Read More…
NAF Statement on FDA Issuing Complete Response Letter for VYGLXIA (troriluzole)
